Clinical Trials Logo

Clinical Trial Summary

The aim of the present study is to investigate the safety, efficacy and cost-effectiveness of empagliflozin, a sodium glucose transporter 2 inhibitor, as an add on therapy to the standard care for refractory ascites in patients with liver cirrhosis


Clinical Trial Description

Midodrine will be added if the blood pressure less than 100/70 mmHg during the follow up period (start by dose 5 mg three times daily and up titrate the dose according to the blood pressure monitoring to maximum dose 12.5 mg three times daily. - Treatment of empagliflozin will be stopped if patient developed any of the following (attack of symptomatic hypoglycemia, hypotention not responding vasopresser agent, complicated urinary tract infection or attack of diabetic ketoascidosis) . - The dose of diuretics will be reduced if marked weight reduction occurred (more than 0.5 kilogram/day in patient with ascites only or more than 1 killogram /day in patients with ascites and lower limb edema). - The diuretics will be stopped temporally if any of the following (renal impairment, attack of hepatic encephalopathy, severe electrolyte imbalance) and permanently if the urine sodium < 30 mEq per day or there are intolerable side effects. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05430243
Study type Interventional
Source Alexandria University
Contact
Status Completed
Phase Phase 2/Phase 3
Start date April 21, 2022
Completion date November 12, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05014594 - Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT Phase 2
Recruiting NCT05793983 - S100A8/A9 and Innate Immunity in Liver Disease
Recruiting NCT05928624 - A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients N/A
Recruiting NCT04221672 - The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy Phase 3
Completed NCT04384523 - A Study of OsrHSA in Adult Healthy Male and Female Volunteers Phase 1
Recruiting NCT05346393 - HRS-AKI Treatment With TIPS in Patients With Cirrhosis N/A
Recruiting NCT04322201 - Continuous Passive Paracentesis for Intra-abdominal Hypertension N/A
Completed NCT05013502 - Empagliflozin in Diuretic Refractory Ascites Phase 1
Withdrawn NCT04109144 - Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis Phase 2
Recruiting NCT05726747 - QOL and Sarcopenia in Patients With Ascites
Completed NCT04569565 - Prospective Evaluation of PleurX Drain for Treatment of Cirrhotic Refractory Ascites N/A
Completed NCT03459378 - Outcome After TIPS
Not yet recruiting NCT06256432 - Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome Phase 2
Recruiting NCT05999773 - SGLT-2 Inhibitors in the Treatment of Ascites
Completed NCT03107091 - Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites Phase 2
Terminated NCT05765253 - Achieving Portal Access With Scorpion Post-Approval Study (APASS) N/A
Recruiting NCT05960006 - A Study to Determine Pharmacokinetic Changes of Ceftriaxone in Patients With Liver Cirrhosis
Completed NCT03191851 - Evaluation of 'Melody' Paracentesis Device for Ascites Therapy N/A
Recruiting NCT05490888 - Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics Phase 1
Not yet recruiting NCT06224023 - Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure